Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Protara Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA) (PROTARA OR THE COMPANY), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED THE RECENT GRANTS OF INDUCEMENT NON-QUALIFIED STOCK OPTIONS AND RESTRICTED STOCK UNITS (RSUS) TO TWO NEWLY-HIRED EMPLOYEES.

PROTARA THERAPEUTICS, INC. REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

PRESENTATION OF INTERIM ANALYSIS FROM APPROXIMATELY 25 SIX-MONTH EVALUABLE BCG-UNRESPONSIVE PATIENTS IN THE ONGOING ADVANCED-2 TRIAL EXPECTED AT A MEDICAL CONFERENCE IN 1Q 2026 DOSING OF FIRST PATIENT IN THRIVE-3 REGISTRATIONAL TRIAL OF IV CHOLINE CHLORIDE IN PATIENTS DEPENDENT ON PARENTERAL SUPPORT ON TRACK FOR 3Q 2025 ON TRACK TO PROVIDE AN INTERIM UPDATE FROM THE PHASE 2 STARBORN-1 TRIAL OF TARA-002 IN PEDIATRIC LMS PATIENTS IN 4Q 2025 CASH, CASH EQUIVALENTS AND INVESTMENTS OFAPPROXIMATELY $146 MILLIONAS OFJUNE 30, 2025, EXPECTED TO SUPPORT PLANNED OPERATIONS INTO MID-2027 NEW YORK, AUG. 11, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC.(NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCEDFINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE. AS WE LOOK TOWARD THE SECOND HALF OF THE YEAR, WE BELIEVE WE ARE WELL POSITIONED TO CONTINUE TO ADVANCE OUR PIPELINE OF POTENTIALLY TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER AND RARE DISEASES, SAID JESSE SHEFFERMAN, CHIEF EXECUTIVE OFFICER OF PROTARA THERAPEUTICS.

PROTARA THERAPEUTICS ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

NEW YORK, AUG. 01, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA) (PROTARA OR THE COMPANY), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED THE RECENT GRANTS OF INDUCEMENT NON-QUALIFIED STOCK OPTIONS AND RESTRICTED STOCK UNITS (RSUS) TO TWO NEWLY-HIRED EMPLOYEES.

NEW YORK, JULY 01, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA) (PROTARA OR THE COMPANY), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED THE RECENT GRANTS OF INDUCEMENT NON-QUALIFIED STOCK OPTIONS AND RESTRICTED STOCK UNITS (RSUS) TO TWO NEWLY-HIRED EMPLOYEES.

NEW YORK, JUNE 30, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC.(NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCEDTHAT THE COMPANY HAS BEEN ADDED AS A MEMBER OF THE BROAD-MARKET RUSSELL 3000 INDEX AS PART OF THE ANNUAL RECONSTITUTION, EFFECTIVE AT THE OPEN OF U.S. EQUITY MARKETS TODAY, JUNE 30, 2025.

PROTARA THERAPEUTICS ANNOUNCES ADDITION TO THE RUSSELL 3000 INDEX

NEW YORK, JUNE 02, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC.(NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCEDTHE APPOINTMENT OF WILLIAM BILL CONKLING AS CHIEF COMMERCIAL OFFICER. HE BRINGS MORE THAN TWO DECADES OF EXPERIENCE DEVELOPING AND COMMERCIALIZING NOVEL CANCER AND RARE DISEASE THERAPEUTICS TO PROTARA.

PROTARA THERAPEUTICS ANNOUNCES APPOINTMENT OF WILLIAM CONKLING AS CHIEF COMMERCIAL OFFICER

NEW YORK, MAY 13, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC.(NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCEDTHAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES:

PROTARA THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

NEW YORK, MAY 08, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC.(NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED A BUSINESS UPDATE.

PROTARA THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

NEW YORK, MAY 01, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC.(NASDAQ: TARA) (PROTARA OR THE COMPANY), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED THE RECENT GRANTS OF INDUCEMENT NON-QUALIFIED STOCK OPTIONS AND RESTRICTED STOCK UNITS (RSUS) TO SIX NEWLY-HIRED EMPLOYEES.

NEW YORK, APRIL 26, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC.(NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED UPDATED RESULTS FROM ITS ONGOING PHASE 2 OPEN-LABEL ADVANCED-2 TRIAL ASSESSING INTRAVESICAL TARA-002, THE COMPANY'S INVESTIGATIONAL CELL-BASED THERAPY, IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS WITH CARCINOMA IN SITU, OR CIS ( TA/T1), WHO ARE BACILLUS CALMETTE-GURIN (BCG)-UNRESPONSIVE OR BCG-NAVE. THE RESULTS WILL BE FEATURED TODAY DURING AN INTERACTIVE POSTER SESSION AT THE AMERICAN UROLOGICAL ASSOCIATION 2025 ANNUAL MEETING IN LAS VEGAS.

PROTARA THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS DEMONSTRATING DURABLE RESPONSES IN THE ONGOING PHASE 2 ADVANCED-2 TRIAL OF TARA-002 IN PATIENTS WITH NMIBC

Protara Therapeutics, Inc.

TARA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Protara Therapeutics, Inc.

TARA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TARA